Metronidazole

General

  • Type: Other antibiotics
  • Dosage Forms:
    • IV
    • PO: 250mg; 375mg; 500mg
  • Common Trade Names: Flagyl

Adult Dosing

General

  • PO
    • 500mg PO q6-8h x 7-10 days
    • First Dose: 500mg PO x 1
  • IV
    • 15mg/kg IV x1, then 7.5mg/kg IV q6h
    • First Dose: 15mg/kg IV x1
  • Max: 1 gram/dose



Indications by Disease

DiseaseDoseContext
Acute diarrhea750mg PO three times daily for 5-10 daysEntamoeba
Acute diarrhea250mg PO q8hrs for 7-10daysGiardia
Acute necrotizing ulcerative gingivitis500mg PO three times daily x 7 daysUncomplicated
Acute tetanus500mg IV (7.5mg/kg) q6hrsActive tetanus
Amebiasis750mg PO q8h x 5-10 daysIntestinal colitis
Ascending cholangitis500mg IV q8hrsCombined with ciprofloxacin
Bacterial vaginosis500 mg PO Twice Daily for 7 daysFirst Line
Bacterial vaginosis500mg PO Twice a day x 7 daysPregnant
Bacterial vaginosis500mg PO Twice a day x 7 daysSexual Assault Prophylaxis
Brain abscess500mg IV q6hrOtogenic
Clostridium difficile500mg PO or IV three times daily for 10 daysNon-Severe (third line)
Diabetic foot infection500mg IV q8hrsInpatient DFI
Diverticulitis500mg PO Q8hrsUncomplicated, Alternative
Diverticulitis500mg PO Q8h x 5 daysUncomplicated, PCN allergy
Epidural abscess (spinal)500mg (7.5mg/kg) q6 hrsEmpiric
Giardia lamblia250mg PO q8h x 5-7 days; Alt: 2 g PO q 24h x 3 daysGiardiasis
Helicobacter pylori250-375mg PO q6h x 10-14 days (in combination)H. pylori
Ludwig's angina500 mg IV q6 hrsImmunocompetent
Ludwig's angina500 mg IV q6 hrsImmunocompromised
Pelvic inflammatory disease500mg IV or PO q12hrInpatient
Pelvic inflammatory disease500mg PO BID x 14 daysOutpatient; recommended empirically by CDC and European guidelines
Peritonitis500mg IV q8hrsPrimary
Peritonitis500mg IV q8hrsAllergy/Prior exposure
Peritonsillar abscess500mg QIDOutpatient
Peritonsillar abscess500mg IV three times dailyInpatient
Postpartum endometritis500mg IV or PO q8hrs>48hrs postpartum; combined with Doxycycline
Trichomonas vaginalis500mg PO BID for 7 daysNon-Pregnant
Trichomonas vaginalis500mg PO BID for 7 daysPregnant
Urethritis in men2 g PO in a single doseRecurrent/Persistent, Trichomonas

Pediatric Dosing

(<1200g)

  • 7.5 mg/kg PO/IV q48h
  • First Dose: 7.5 mg/kg PO/IV x 1

(>1200g AND <1 Month Old)

  • <7 days old
    • 7.5-15 mg/kg/day PO/IV q12-24h
    • First Dose: 7.5-15 mg/kg PO/IV x 1
  • >7 days old
    • 15-30 mg/kg/day PO/IV q12h
    • First Dose: 7.5-15 mg/kg PO/IV x 1

(>1 Month Old)

  • 30 mg/kg/day PO/IV q6h
  • First Dose: 7.5 mg/kg PO/IV x 1
  • Max: 4 g/day



Indications by Disease

DiseaseDoseContext
Acute tetanus7.5mg/kg IV q6hrs (max 500mg/dose) x 7-10 daysPediatric Active tetanus
Brain abscess7.5mg/kg IV q6hrs (max 500mg)Pediatric Empiric
Clostridium difficile7.5mg/kg PO/IV TID x 10 days (max 500mg/dose)Pediatric Non-Severe (third line)
Epidural abscess (spinal)7.5mg/kg IV q6hrs (max 500mg)Pediatric Empiric
Infectious tenosynovitis7.5mg/kg IV four times dailyPediatrics
Ludwig's angina7.5mg/kg IV q6hrs (max 500mg)Pediatric Immunocompetent
Ludwig's angina7.5mg/kg IV q6hrs (max 500mg)Pediatric Immunocompromised
Peritonitis7.5mg/kg IV q8hrs (max 500mg)Pediatric
Peritonsillar abscess7.5mg/kg IV q8hrs (max 500mg/dose)Pediatric Inpatient
TetanusSame as Standard Pediatric Age/Weight DosingTetanus

Special Populations

  • Pregnancy: B
  • Lactation: Safety conditional
  • Renal Dosing
    • Adult
      • No adjustment for renal insufficiency
      • Hemodialysis: Give dose after dialysis
      • Peritoneal Dialysis: No supplement
    • Pediatric
      • CrCl <10: Decrease dose 50%
      • Hemodialysis: Give dose after dialysis
      • Peritoneal Dialysis: No supplement
  • Hepatic Dosing (Adult & Pediatric)
    • Severe impairment: decrease dose, amount not defined

Contraindications

  • Black Box: carcinogenic in mice and rats; avoid unnecessary use; reserved for approved conditions
  • Allergy to class/drug
  • Pregnancy (single 2 dose retimen)
  • Alcohol use within 3 days
  • Disulfiram use within 14 days

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 8h
  • Metabolism: Liver; CYP450: 2C9 inhibitor
  • Excretion: Urine (70%); feces (15%)
  • Mechanism of Action: Bactericidal

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G R
Strep. Pneumoniae R
Viridans strep X1
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium R
MSSA R
MRSA R
CA-MRSA R
Staph. Epidermidis R
C. jeikeium R
L. monocytogenes R
Gram Negatives N. gonorrhoeae R
N. meningitidis R
Moraxella catarrhalis R
H. influenzae R
E. coli R
Klebsiella sp R
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp X1
Serratia marcescens R
Salmonella sp R
Shigella sp R
Proteus mirabilis X1
Proteus vulgaris R
Providencia sp. X1
Morganella sp. X1
Citrobacter freundii X1
Citrobacter diversus X1
Citrobacter sp. X1
Aeromonas sp X1
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia R
Stenotrophomonas maltophilia R
Yersinia enterocolitica R
Francisella tularensis R
Brucella sp. R
Legionella sp. R
Pasteurella multocida X1
Haemophilus ducreyi R
Vibrio vulnificus R
Misc Chlamydophila sp R
Mycoplasm pneumoniae R
Rickettsia sp R
Mycobacterium avium R
Anaerobes Actinomyces R
Bacteroides fragilis S
Prevotella melaninogenica S
Clostridium difficile S
Clostridium (not difficile) S+'
Fusobacterium necrophorum S
Peptostreptococcus sp. I

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Sanford Guide to Antimicrobial Therapy 2014